Evaxion Biotech Competitors and Similar CompaniesClear all

Evaxion Biotech's competitors and similar companies include Repare Therapeutics, C4 Therapeutics, Ensem Therapeutics and Remedy Plan.

	Evaxion Biotech Evaxion Biotech A/S is a company focused on the development of vaccines against cancer and infectious diseases.	Repare Therapeutics Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.	C4 Therapeutics C4 Therapeutics is a clinical-stage biotechnology company specializing in targeted protein degradation.	Ensem Therapeutics Ensem Therapeutics is a drug discovery and development company focused on oncology.	Remedy Plan Remedy Plan Therapeutics is a biotechnology company developing drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
Founding Date	Founding Date 2008	Founding Date 2016	Founding Date 2015	Founding Date 2021	Founding Date 2011
Type	Type Public	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare artificial intelligence biotech drug development oncology platform	Tags Healthcare biotech drug development oncology platform	Tags Healthcare biotech drug development oncology pharma platform	Tags Healthcare artificial intelligence biotech clinical research drug development oncology	Tags Healthcare biotech drug development oncology pharma platform
Locations	Locations København, DK HQ	Locations Montréal, CA HQ Cambridge, US	Locations Watertown, US HQ	Locations Waltham, US HQ Shanghai, CN	Locations HQ
Employees	Employees 558% decrease	Employees 129	Employees 1045% decrease	Employees 278% increase	Employees 15
Valuation ($)	Valuation ($) 16.2 m	Valuation ($) 152.4 m	Valuation ($) 416 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $7.5m (FY, 2025)	Revenue (est.) $53.5m (FY, 2024)	Revenue (est.) $35.9m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $7.5m (FY, 2025)	Gross profit $53.5m (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ($7.7m) (FY, 2025)	Net income ($84.7m) (FY, 2024)	Net income ($105m) (FY, 2025)	Net income N/A	Net income N/A
Operating ⚠
Patents (US)	Patents (US) 6 (FY, 2020)	Patents (US) N/A	Patents (US) 2 (Q2, 2020)	Patents (US) N/A	Patents (US) N/A
Funding
Total funding raised	Total funding raised $ 17m	Total funding raised $ 150.5m	Total funding raised $ 223m	Total funding raised $ 67m	Total funding raised $ 10.1m